APA (7th ed.) Citation

(2021). EGFR inhibitors plus bevacizumab are superior than EGFR inhibitors alone as first-line setting in advanced NSCLC with EGFR mutations and BIM deletion polymorphisms (BIM-CLICaP).

Chicago Style (17th ed.) Citation

EGFR Inhibitors Plus Bevacizumab Are Superior than EGFR Inhibitors Alone as First-line Setting in Advanced NSCLC with EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP). 2021.

MLA (8th ed.) Citation

EGFR Inhibitors Plus Bevacizumab Are Superior than EGFR Inhibitors Alone as First-line Setting in Advanced NSCLC with EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP). 2021.